Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Hi guys. I'm new here. I've joined these forums due to a recommendation from a friend of mine. He says that you guys here can offer some good programming repair work if guys like me are in trouble.

Recursion Pharmaceuticals, Inc (($RXRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals, ...

As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...

Amidst the artificial intelligence (AI) revolution and a rapidly shifting landscape in drug development, Recursion Pharmaceuticals (NASDAQ: RXRX) is aiming to position itself at the intersection of ...

Recursion reported fourth-quarter revenue of $10.89 million, which missed the consensus estimate of $20.35 million. The company reported a quarterly loss of 42 cents per share, which beat estimates ...